Rivernorth Capital Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Rivernorth Capital Management’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-246,674	Closed	-$2.49M	–	798
2022 Q4	$2.49M	Buy	246,674 +25,000	+11%	+$250K	0.11%	171
2022 Q3	$2.2M	Hold	221,674	–	–	0.1%	204
2022 Q2	$2.19M	Hold	221,674	–	–	0.09%	197
2022 Q1	$2.18M	Sell	221,674 -3,324	-1%	-$32.7K	0.08%	208
2021 Q4	$2.21M	Hold	224,998	–	–	0.09%	180
2021 Q3	$2.19M	Buy	+224,998	New	+$2.18M	0.12%	137

Rivernorth Capital Management's BIOT Position: Q1 2023 in Review

Rivernorth Capital Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 246,674 shares — an estimated $2.49M sold.

Rivernorth Capital Management first reported a position in BIOT in Q3 2021 and held it in 6 quarters. The position peaked at $2.49M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Rivernorth Capital Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Rivernorth Capital Management sold 246,674 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $2.49M.
Rivernorth Capital Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q3 2021 and held it in 6 quarters.
Rivernorth Capital Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $2.49M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Rivernorth Capital Management's 13F filing for Q1 2023, filed 15 May 2023.